SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:gup.ub.gu.se/247741"
 

Search: id:"swepub:oai:gup.ub.gu.se/247741" > Secondary immunodef...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Friman, Vanda,1952Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine (author)

Secondary immunodeficiency in lymphoproliferative malignancies

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • 2016-07-12
  • Wiley,2016

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/247741
  • https://gup.ub.gu.se/publication/247741URI
  • https://doi.org/10.1002/hon.2323DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:134705118URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Secondary immunodeficiencies occur as a consequence of various diseases, including hematological malignancies, and the use of pharmacological therapies, such as immunosuppressive, anti-inflammatory, and biological drugs. Infections are the main cause of morbidity and mortality in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) patients. Recent advances in treatment have prolonged the duration of remission and the time between relapse phases in MM and CLL patients. However, managing multiple relapses and the use of salvage therapies can lead to cumulative immunosuppression and a higher risk of infections. The pathogenesis of immune deficiency secondary to lymphoproliferative malignancy is multifactorial including disease- and treatment-related factors. Supportive treatment, including early vaccination, anti-infective prophylaxis, and replacement immunoglobulin, plays a key role in preventing infections in MM and CLL. This article provides an overview of the basic immunology necessary to understand the pathogenesis of secondary immunodeficiency and the infectious complications in MM and CLL. We also discuss the evidence supporting the role of prophylactic replacement immunoglobulin treatment in patients with antibody failure secondary to MM and CLL and the indications for its use. Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Winqvist, O.Karolinska Institutet (author)
  • Blimark, Cecilie (author)
  • Langerbeins, P. (author)
  • Chapel, H. (author)
  • Dhalla, F. (author)
  • Göteborgs universitetInstitutionen för biomedicin, avdelningen för infektionssjukdomar (creator_code:org_t)

Related titles

  • In:Hematological Oncology: Wiley34:3, s. 121-1320278-02321099-1069

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view